Success Story: Molecular Biology Researcher Secures I-140 NIW Approval for Advancing Personalized Cancer Treatment
Client’s Testimonial:
“I had a positive experience working with Chen Immigration Law Group on my EB-2 NIW petition. The team was professional, responsive, and well organized throughout the process. I especially appreciated their efforts in identifying the strengths of my research background, organizing supporting evidence, and crafting a compelling petition letter that clearly demonstrated how my work aligned with the NIW requirements. I’m very pleased that my I-140 was approved and grateful for their dedication and expertise. I would recommend their services to researchers and professionals pursuing an EB-2 NIW petition.”
On October 10th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Computational Biologist in the Field of Molecular Biology (Approval Notice).
General Field: Molecular Biology
Position at the Time of Case Filing: Computational Biologist
Country of Origin: China
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: October 10th, 2026
Processing Time: 7 months, 14 days (Premium Processing Upgrade Requested)
Case Summary:
Advancements in molecular biology are creating new opportunities to understand why patients respond differently to medical treatments. North America Immigration Law Group (Chen Immigration Law Associates) successfully secured I-140 EB-2 National Interest Waiver (NIW) approval for a researcher specializing in molecular biology. Holding a master’s degree in bioinformatics, the client has developed expertise in combining biological research with computational approaches to investigate disease progression and improve treatment strategies.
Our petition emphasized the national importance of this endeavor by connecting the client's research to broader U.S. healthcare needs, particularly the development of more effective cancer treatments and the advancement of precision medicine. We demonstrated how improved understanding of treatment responses could contribute to better clinical decision-making, potentially reduce complications, and support efforts to address the healthcare burden associated with cancer.
The client's academic and research background also provided important evidence of his qualifications. His scholarly record included 1 peer-reviewed journal article, 4 research abstracts, 1 preprint, and 1 work in preparation, with 36 citations to his published research. Notably, his peer-reviewed article ranked among the top 10% most-cited publications in molecular biology and genetics for its publication year. This comparative evidence helped establish that the client's research had attracted meaningful scholarly attention relative to other publications in the field.
Beyond these numerical achievements, we highlighted how independent researchers had incorporated the client's findings into their own investigations. His research had been referenced in studies examining biological processes associated with inflammation, disease progression, and treatment resistance. These examples provided evidence that his contributions were useful to other researchers and helped demonstrate his ability to advance further investigations in molecular biology.
To strengthen the petition, we also submitted 4 letters of recommendation from independent experts who provided professional assessments of the client's scientific contributions, research experience, and ability to advance his proposed endeavor. Their evaluations complemented the documentary evidence by offering additional perspectives on the significance of his work and its relevance to ongoing biomedical research.
By presenting the client's education, research accomplishments, independent scholarly recognition, and future research plans within the Matter of Dhanasar framework, our legal team demonstrated how his qualifications and proposed endeavor supported NIW eligibility. The resulting I-140 NIW approval reflects a successful petition strategy that connected his established research contributions with the broader importance of advancing personalized cancer care in the United States.